Isolated Anti-HBc Serological Profile in HIV Infected Patients: Immunological, Virological Characteristics and Response to Hepatitis B Vaccination (ANRSHBEP03)
Study of Immunological, Virological, Serological Characteristics of HIV+ Patients Harboring Isolated Anti-HBc Profile and Response to Hepatitis B Vaccination
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Dijon, France
- CHU Dijon
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- HIV+ adults patients
- negative HBsAg
- negative a-HBs Ab
- positive HBc Ab
- without HBV - vaccination
- CD4 cell above 200 /mm3
- HIV viral load below 50 copies/mL
Exclusion Criteria:
- positive HBs antigenemia in the past
- transaminitis above fivefold upper normal limit
- PT<50% or Platelet <50 000/mm3
- ongoing opportunistic infection
- ongoing or recent systemic corticoid or immunomodulatory therapy, splenectomy, pregnancy, contra-indication to intramuscular injection, familial history of neurological disease.
Study Plan
How is the study designed?
Design Details
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
vaccination
Anti-HBV vaccine injection
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Evaluation of immunological, virological and serological characteristics associated to "anti-HBc isolated" profile
Time Frame: at Day 0, inclusion visite
|
at Day 0, inclusion visite
|
|
Average titers of anti-HBs Ab
Time Frame: at 4 weeks, 28 weeks and 18 months after the first vaccination HBV
|
at 4 weeks, 28 weeks and 18 months after the first vaccination HBV
|
|
Analysis of B-cell phenotype and maturation
Time Frame: at baseline and at week 28
|
at baseline and at week 28
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of patients with HBsAb titers as protective titer>10 IU/L
Time Frame: at 4 weeks,28 weeks and 18 month after the first dose HBV vaccin
|
at 4 weeks,28 weeks and 18 month after the first dose HBV vaccin
|
|
Detection of IgG+ memory B cells specific for HBcAg or HBs Ag
Time Frame: at baseline and 28 weeks after the first dose HBV vaccin
|
at baseline and 28 weeks after the first dose HBV vaccin
|
|
- Detection of HBV preS2 and S-specific T cells
Time Frame: at day 0 and week 28
|
at day 0 and week 28
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Lionel Piroth, CHU Dijon
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- ANRS HB EP 03 CISOVAC
- 2010-A00511-38 (Other Identifier: ANSM)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.